p16INK4a Antibody / CDKN2A

Overview

p16INK4a is a tumor suppressor protein. It is a specificinhibitor of cdk4/cdk6, and a tumorsuppressor involved inthe pathogenesis of a variety of malignancies. Recentanalyses of the p16INK4a gene revealed homozygousdeletions, nonsense, missense, or frameshift mutations inseveral human cancers. Although the frequency of p16INK4aabnormalities is higher in tumor derived cell lines than inunselected primary tumors, significant subsets of clinicalcases with aberrant p16INK4a gene have been reportedamong melanomas, gliomas, esophageal, pancreatic, lung,and urinary bladdercarcinomas, and some types of leukemia.Expression of p16INK4a (p16 positive) is highly correlatedwith human papilloma virus (HPV) infection in head and necksquamous cell carcinomas (HNSCC). p16 status is animportant prognostic indicator in HNSCC and the p16positive/HPV16 negative group is likely a distinct subgrouplacking any HPV genotype.

This anti-CDKN2A antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone CDKN2A/4499, Mouse IgG2a, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: CDKN2A
• Format: Purified
• Localization: Nuclear and cytoplasmic
• Species reactivity: Human
• Applications (listed): IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone CDKN2A/4499, Mouse IgG2a, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

CDKN2A is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling CDKN2A expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link CDKN2A signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.